Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19985024 | 0.83 | SLC6A9 (0.43) | HTT | |
| SCHEMBL18286135 | 0.82 | HSP90AA1 (0.52) | ALDH1A1HTTNPC1RAB9AMEN1 | |
| SCHEMBL19985025 | 0.80 | ABCB1 (0.43) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL19971955 | 0.79 | P2RX7 (0.44) | MAPTSMN1; SMN2ATMTP53 | |
| SCHEMBL18283321 | 0.78 | PREP (0.62) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| SCHEMBL18286158 | 0.77 | PREP (0.58) | ALDH1A1MEN1KMT2AGAAATM | |
| SCHEMBL24176653 | 0.76 | SLC6A9 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19985023 | 0.76 | SLC6A9 (0.47) | MEN1KMT2A | |
| SCHEMBL22055741 | 0.73 | POLB (0.57) | HTTMEN1KMT2A | |
| SCHEMBL27261597 | 0.72 | PREP (0.55) | ALDH1A1MEN1KMT2AGAAPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131972-A | Microsatellite stabilized colorectal cancer combination therapy based on PCSK9 inhibitors | 广东省人民医院 | 2025-06-13 | — | — | CN | claimed |
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | claimed |
| CN-120131972-A | Microsatellite stabilized colorectal cancer combination therapy based on PCSK9 inhibitors | 广东省人民医院 | 2025-06-13 | — | — | CN | disclosed |
| CN-117959440-A | Application of PCSK9 in preparation of medicine for treating oligospermia | 深圳大学总医院 | 2024-05-03 | — | — | CN | disclosed |
| CN-114344466-B | Use of PCSK9 inhibitors for the preparation of products for the treatment of keratinization disorders | 陈敏 | 2024-01-02 | — | — | CN | disclosed |
| US-20230346773-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | CHEN, MIN (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230346773-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | CHEN, MIN (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230346773-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | CHEN, MIN (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-4268817-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | Chen, Min (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-113876956-B | Application of PCSK9 inhibitor in preparation of product for promoting skin pigmentation | 陈敏 | 2023-07-04 | — | — | CN | disclosed |
| CN-113876955-B | Use of PCSK9 inhibitors for the preparation of hair growth promoting products | 陈敏 | 2023-06-27 | — | — | CN | disclosed |
| CN-115120730-A | Application of PCSK9 inhibitor in preparation of product for preventing and treating scars | 陈敏 | 2022-09-30 | — | — | CN | disclosed |
| CN-114344466-A | Application of PCSK9 inhibitor in preparation of product for treating hyperkeratosis diseases | 陈敏 | 2022-04-15 | — | — | CN | disclosed |
| US-20220073647-A1 | APPLICATION OF PCSK9 INHIBITORS IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES | CHEN MIN (CN) | 2022-03-10 | — | — | US | disclosed |
| WO-2022002160-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | 陈敏 | 2022-01-06 | — | — | WO | disclosed |
| US-11214625-B2 | Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases | CHEN MIN (CN) | 2022-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | MAPT 2814/4885ALDH1A1 4302/4885CYP2C19 3261/4885 |
| US-20220073647-A1 | APPLICATION OF PCSK9 INHIBITORS IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES | PCSK9, PCSK6, PCSK7 | MAPT 281/4885ALDH1A1 4300/4885CYP2C19 2620/4885 |
| US-20230346773-A1 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | PCSK9, PCSK7, PCSK6 | MAPT 1043/4885ALDH1A1 4876/4885CYP2C19 4469/4885 |
| US-11214625-B2 | Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases | PCSK9, PCSK6, PCSK7 | MAPT 277/4885ALDH1A1 4227/4885CYP2C19 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.